<DOC>
	<DOCNO>NCT00745511</DOCNO>
	<brief_summary>This randomize , multi-center , double blind , 3 arm , phase I/II pilot study evaluate safety efficacy treatment ORA102 combine Avastin ( Bevacizumab ) versus Avastin alone , patient neo-vascular age relate macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Pilot Study Evaluate Safety Efficacy Treatment With ORA102 Combined With Avastin ( Bevacizumab ) Versus Avastin Alone , Patients With Neovascular Age Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects provide informed consent , include signing informed consent form Subject able willing comply study protocol Subject must best correct visual acuity ETDRS 20/40 20/320 study eye Subjects whose CNV lesion study eye contain 25 % scar and/or atrophy Women must postmenopausal 1 year surgically sterilize . If , negative serum pregnancy test require within 14 day randomization Pregnant lactate woman Patients severe myocardial disease coronary occlusion Patients severe personality disorder , suicidal risk psychosis Patients previous history CVA Evidence liver dysfunction bilirubin level twice upper limit normal value OR ALT/AST &gt; 1.5x upper limit normal value Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatment related complication</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>AMD</keyword>
	<keyword>Avastin</keyword>
	<keyword>ORA102</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>neo-vascular age relate macular degeneration ( AMD )</keyword>
</DOC>